Investing.com UK - Financial Markets Worldwide
🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Shares

Artivion Stock Plunges Apixaban Vs. Warfarin Trial Setback, Reaffirms Annual Guidance

Published 23/09/2022, 15:08
© Reuters. Artivion Stock Plunges Apixaban Vs. Warfarin Trial Setback, Reaffirms Annual Guidance

  • Artivion Inc (NYSE: AORT) has stopped the PROACT Xa trial to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban rather than on warfarin.
  • The decision was based on the recommendation of the independent Data and Safety Monitoring Board (DSMB) of the trial due to a lack of evidence supporting the non-inferiority of apixaban to warfarin for valve thrombosis and thromboembolism.
  • The PROACT Xa trial randomized patients having an On-X aortic valve replacement to receive either warfarin or apixaban as their anticoagulant to prevent blood clots.
  • The trial began enrolling in April 2020. The DSMB found that blood clots occurred more frequently in patients receiving apixaban.
  • Continuing the trial was unlikely to achieve the primary endpoint while possibly exposing patients to increased risk.
  • Physician investigators are being notified to change patients in the apixaban arm of the trial back to warfarin.
  • The company reiterated the FY22 outlook of delivering double-digit top-line growth, expanding gross margins, and accelerated adjusted EBITDA growth through 2024.
  • "We had committed approximately $10 million in annual funding to this study through 2024 and will now redirect these funds to other development opportunities and incremental EBITDA and cash flow in 2023 and 2024," said Pat Mackin, Chairman, President & CEO.
  • Price Action: AORT shares are down 17.9% at $15.18 on the last check Friday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.